Integrates potency analysis and immunophenotyping to streamline cell therapy R&D

整合效力分析和免疫表型分析以简化细胞疗法的研发

Fully automated, standalone platform with single-cell resolution

具有单细胞分辨率的全自动独立平台

BOLOGNA, Italy, Jan. 17, 2024 /PRNewswire/ -- Cellply S.r.l. (Cellply) a leading developer of analytical tools for research and quality control within the 'Cell Therapy' sector, today announced the launch of its flagship product VivaCyte.®VivaCyte - a tool capable of reducing development times, costs, and risks - is the first fully integrated platform of its kind to characterize the complex functionality and mechanism of action of potential cellular immunotherapies rapidly and comprehensively..

意大利博洛尼亚，2024年1月17日/PRNewswire/-Cellply S.r.l.（Cellply）是“细胞疗法”领域研究和质量控制分析工具的领先开发商，今天宣布推出其旗舰产品VivaCyte。®VivaCyte是一种能够减少开发时间、成本和风险的工具，是同类产品中第一个全面集成的平台，可以快速全面地表征潜在细胞免疫疗法的复杂功能和作用机制。。

Continue Reading

继续阅读

Cellply launches its end-to-end single cell potency characterization platform VivaCyte - to streamline cell therapy R&D

Cellply推出了端到端的单细胞效力表征平台VivaCyte，以简化细胞疗法的研发

Post this

发布此

Cellply leaders Emiliano Spagnolo and Massimo Bocchi with the new VivaCyte single cell potency characterization platform

Cellply领导者Emiliano Spagnolo和Massimo Bocchi使用新的VivaCyte单细胞效力表征平台

VivaCyte enables rapid testing of multiple cell therapy candidates from multiple process options, against multiple target tumor cells. Unprecedented depth of analysis combined with parallel screening of multiple conditions in a single run, delivers reproducible immune cell characterization and single-cell functional characterization at a fraction of the time currently needed by existing analytical tools..

VivaCyte能够针对多个靶肿瘤细胞快速测试来自多个过程选项的多种细胞治疗候选物。前所未有的分析深度结合在一次运行中并行筛选多种条件，可以在现有分析工具当前所需时间的一小部分时间内提供可重复的免疫细胞表征和单细胞功能表征。。

'Helping the biopharmaceutical industry to identify and develop the most effective versions of their cellular therapies is our goal,' stated Emiliano Spagnolo, CEO, Cellply. 'We have seen an explosion in the demand for a characterization platform capable of rapidly measuring the potential effectiveness of these game-changing cellular immunotherapies and accelerating their development.

Cellply首席执行官埃米利亚诺·斯帕格罗（EmilianoSpagnolo）表示：“帮助生物制药行业识别和开发最有效的细胞疗法是我们的目标。”我们已经看到对能够快速测量这些改变游戏规则的细胞免疫疗法的潜在有效性并加速其发展的表征平台的需求激增。

With its ability to rapid deliver actionable results with minimal hands-on time, we are excited to be launching VivaCyte to meet this need.'At the heart of VivaCyte is the patented CC-Array® chip and microfluidic technology that generates up to 153,600 co-cultures per run. In combination with AI-powered automated image analysis, immune cell subpopulations containing higher numbers of active killer and serial killer cells can be rapidly identified and unified potency scores calculated.   Massimo Bocchi, PhD, co-founder and Chief Strategy Officer, Cellply, added: 'Until now there has been no simple methodology to evaluate supercharged subpopulations within a heterogeneous cell therapy sample which retain a phenotype capable of serial killing.

凭借其以最少的动手时间快速交付可行结果的能力，我们很高兴推出VivaCyte来满足这一需求。”VivaCyte的核心是获得专利的CC Array®芯片和微流体技术，每次运行可产生多达153600个共培养物。结合AI驱动的自动图像分析，可以快速识别含有更多活性杀伤细胞和连续杀伤细胞的免疫细胞亚群，并计算统一的效力评分。Cellply联合创始人兼首席战略官Massimo Bocchi博士补充道：“到目前为止，还没有简单的方法来评估异质细胞治疗样本中的增压亚群，这些亚群保留了能够连续杀伤的表型。

With the multiparametric capability of VivaCyte, single-cell cytotoxicity, serial killing, and phenotype can be determined on the same set of cells within a heterogeneous population. With this information, identification of donors or cell therapy batches or manufacturing processes featuring higher serial killing activity and better killing kinetics can enable the use of more potent products requiring fewer immune cells to generate a response in the patient.' There are over 2,700 cellular therapies currently in development worldwide*.

利用活细胞的多参数能力，可以在异质群体中的同一组细胞上确定单细胞毒性，连续杀伤和表型。有了这些信息，鉴定具有更高连续杀伤活性和更好杀伤动力学的供体或细胞治疗批次或制造过程，可以使用需要更少免疫细胞才能在患者体内产生反应的更有效的产品。”目前全球有2700多种细胞疗法正在开发中*。

The ability to determine the potential effectiveness of these therapies, at scale, and to be able to directly compare the.

能够大规模确定这些疗法的潜在有效性，并能够直接比较。